SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1971)12/16/2003 11:48:41 PM
From: Miljenko Zuanic  Read Replies (1) of 3044
 
They have 7 years exclusivity for Leprosy. Why they will again get 7 years for MM? So, every seven years you get new orphan drug indication approval, and your exclusivity is going forever!!! In theory it works, in practice...I do not know? How knows something is welcome to comment.

Is STEPS program for real patentable and enforceable? Is this FDA invention, applied *by must* by CELG, or it is due to *brain wash*?

For almost $400M in sale (to be) and very nice profit margin, I think more than one generic company will challenge CELG Thal. IP and marketing right. Remember, FDA DID NOT approve CELG Thalidomide for Leprosy. They approved ANY (ANY!!!) T, but only CELG applied for marketing right, so far.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News